DUR system likely to be further promoted

Published: 2004-08-13 07:00:00

Updated: 2004-08-13 07:00:00

With belated move of the Korea Food and Drug Administration to ban 75 companies from producing and selling 167 products containing phenylpropanolamine (PPA), there is a social consensus on safer use of drugs and this mood is expected to further promote the drug utilization review (DUR) system.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK